Skip to main content
GemVax & KAEL Co.,Ltd. logo

GemVax & KAEL Co.,Ltd. — Investor Relations & Filings

Ticker · 082270 ISIN · KR7082270000 KO Manufacturing
Open in API
Filings indexed 647 across all filing types
Latest filing 2026-04-28 Legal Proceedings Report
Country KR South Korea
Listing KO 082270

About GemVax & KAEL Co.,Ltd.

https://gemvax.com/

GemVax & KAEL is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics. Its lead drug candidate is GV1001, a synthetic peptide composed of 16 amino acids, which has demonstrated multiple actions including the modulation of neuroinflammation and reduction of oxidative stress. The company's development pipeline primarily targets neurodegenerative diseases, such as Alzheimer's disease and Progressive Supranuclear Palsy (PSP). Other therapeutic areas under investigation include pancreatic cancer and benign prostatic hyperplasia. GemVax & KAEL is actively advancing its programs through clinical trials to evaluate the efficacy and safety of its novel treatments.

Recent filings

Filing Released Lang Actions
기타경영사항(자율공시) (대법원 2026 다 202990 손해배상(기) 소송 취하 합의 체결)
Legal Proceedings Report Classification · 90% confidence The document is a voluntary corporate disclosure detailing the withdrawal of a Supreme Court appeal, the settlement terms of a damages lawsuit (case numbers, courts, parties, settlement payments, issuance of convertible bonds, share acquisitions), and related litigation history. This matches the definition of a Legal Proceedings Report (updates on significant lawsuits/regulatory actions).
2026-04-28 Korean
타법인주식및출자증권취득결정
M&A Activity Classification · 80% confidence The document is headed “타법인 주식 및 출자증권 취득결정” (Decision to acquire shares and investment securities of another corporation) and provides full board‐approved details of acquiring a 35.85% stake in a third‐party company by cash and convertible bonds. This is not a share buy‐back (POS), share issue by the reporting company (SHA), nor simply a fundraising update (CAP). It describes a strategic acquisition of equity in another entity, which is categorized under M&A Activity (TAR).
2026-04-28 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Capital/Financing Update Classification · 81% confidence The document is a stock pledge (담보제공) contract announcement by the major shareholder along with a correction, detailing financing arrangements (loan amounts, collateral periods, contract dates). This is not a quarterly or annual report, nor a director share sale/purchase, nor a share issue. It clearly describes a financing activity and capital structure update via share collateral agreements, matching the “Capital/Financing Update” category (CAP).
2026-04-20 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 92% confidence The document is a Korean large shareholding status report (“주식등의 대량보유상황보고서”) filed under the Capital Markets Act (자본시장과 금융투자업에 관한 법률 제147조), detailing an entity’s and its related parties’ shareholdings, changes, and reasons. It is a regulatory disclosure of major shareholding changes crossing thresholds rather than a financial report, management announcement, dividend notice, or other category. This aligns exactly with “Major Shareholding Notification (Code: MRQ).”
2026-04-20 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Capital/Financing Update Classification · 85% confidence The document is a statutory disclosure regarding the execution (and correction thereof) of a stock pledge (share collateral) agreement tied to the company’s financing. It details the loan amounts, collateral‐provider (the major shareholder), pledged shares, pledge periods, execution conditions, and related financial data. This is not an annual report, earnings release, board change, director trade, dividend notice, proxy statement, or share issuance. It falls squarely under an update on the company’s financing activity—specifically, a secured debt financing using share collateral. Therefore, the correct category is “Capital/Financing Update” (CAP).
2026-04-15 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Regulatory Filings Classification · 65% confidence The document is a Korean regulatory disclosure detailing a stock pledge (주식 담보제공 계약) by the major shareholder to secure borrowings. It includes contract dates, loan amounts, collateral periods, and information on the debtor company. There is no indication that this is an annual or interim report, audit, earnings release, or a director share transaction. It is not announcing a share issuance or buyback, nor a dividend, M&A, or management change. As this is a miscellaneous regulatory notice required under Korean securities law—and does not neatly fit other specific categories—it falls under the fallback category “Regulatory Filings (RNS).”
2026-04-13 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.